Literature DB >> 17348449

Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.

Xavier Filella1, Joan Alcover, Rafael Molina, Pilar Luque, Juan M Corral, Josep M Augé, Francisca Coca.   

Abstract

BACKGROUND: Free prostate-specific antigen (fPSA), the minor form of total PSA, contains different molecular subforms, including BPSA and proPSA. Whereas BPSA is associated with benign prostate hyperplasia, proPSA is associated with prostate tumor. PATIENTS AND METHODS: The serum levels of PSA, fPSA and proPSA were measured using automated electrochemiluminescent immunoassays (Elecsys 2010, Roche Diagnostics) in 87 patients with prostate cancer and 138 patients with benign prostate hyperplasia. Also, we calculated the derived tests of these assays through the subtraction or the ratio between the measured tests.
RESULTS: Receiver operating characteristics curves were used for comparison of the diagnostic utility of tests assessed. The biggest areas were obtained for the free/total PSA ratio (0.705), the calculated Bfree PSA/total PSA ratio (0.719) and the calculated Bfree PSA/bound PSA ratio (0. 726).
CONCLUSION: Applying a multivariate logistic regression analysis, it was determined that the combination of the proPSA concentration, the proPSA/total PSA ratio and the calculated Bfreeltotal PSA ratio improves the area under the curve obtained for individual tests (0.753). ProPSA may be useful in the diagnosis of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17348449

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  1 in total

1.  Systematic Differences Between Total and Free Prostate-Specific Antigen Immunoassays: Comparison Using Passing and Bablok Regression.

Authors:  Nafija Serdarevic; Pradeep Dabla; Adina Elena Stanciu
Journal:  Indian J Clin Biochem       Date:  2019-02-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.